Romosozumab-aqqg
Potential Risk of Myocardial Infarction, Stroke and Cardiovascular Death
- EVENITY may increase the risk of myocardial infarction, stroke, and cardiovascular death. EVENITY should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY should be discontinued.
Patient Counseling Information
Medication Guides
Package Inserts
Updated April 2019